Clinical Trials Logo

Filter by:
NCT ID: NCT05308225 Active, not recruiting - Multiple Myeloma Clinical Trials

Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

Start date: February 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a two-stage phase 1b/2a, open-label, multicenter, dose-escalation study of STI-6129 administered intravenously once in a 4-week cycle in subjects with relapsed or refractory multiple myeloma.

NCT ID: NCT05307328 Active, not recruiting - Clinical trials for Cortisol; Hypersecretion

SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

RESCUE
Start date: September 1, 2022
Phase: Phase 2
Study type: Interventional

This is a randomized, placebo-controlled, study of SPI-62 in subjects with ACTH-dependent Cushing's syndrome caused by a non-adrenal tumor. Subjects will receive each of the following 2 treatments for 24 weeks: SPI-62 and matching placebo with the option of long-term extension.

NCT ID: NCT05306353 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

CD40L Antagonism in Rheumatoid Arthritis (RA)

CONTROL-RA
Start date: July 25, 2023
Phase: Phase 2
Study type: Interventional

The primary objective is to determine if the addition of a 12-week course of treatment with VIB4920 to TNFi treatment will result in improved clinical disease control in patients with RA who have had an inadequate response to a TNFi.

NCT ID: NCT05306288 Active, not recruiting - Lung Cancer Clinical Trials

CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in Lung

DELFI-L201
Start date: April 7, 2022
Phase:
Study type: Observational

CASCADE-LUNG is an event-driven, multisite, prospective, observational, blood specimen collection study in the elevated-risk lung cancer screening population. The primary objective is to determine the sensitivity and specificity of the Delfi Lung Cancer ScreeningTest (DLCST).

NCT ID: NCT05305989 Active, not recruiting - Clinical trials for Chronic Graft-versus-host-disease

Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213

Start date: February 23, 2022
Phase: Phase 2
Study type: Interventional

Extended Treatment and Follow-up of Subjects Treated with Belumosudil in Study KD025-208 or Study KD025-213

NCT ID: NCT05305950 Active, not recruiting - Pediatric Cancer Clinical Trials

Barriers and Facilitators in Access to OT/PT in Pediatric Cancer Survivors

Start date: December 17, 2021
Phase:
Study type: Observational

This study aims to identify the modifiable facilitators and barriers to occupational and physical therapy care for children during and after cancer treatment that may be contributing to disparities in health outcomes. The investigators will identify these facilitators and barriers by surveying and interviewing healthcare administrators at MD Anderson Cancer center. The investigators will also survey and interview physicians, advanced practice providers, and occupational and physical therapists to obtain their feedback on these issues.

NCT ID: NCT05304936 Active, not recruiting - Clinical trials for Advanced Pancreatic Carcinoma

HCW9218 for Advanced Pancreatic Cancer

Start date: October 17, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1b/2, open-label, multi-center, competitive enrollment and dose-escalation study of HCW9218 in patients with advanced/metastatic pancreatic cancer.

NCT ID: NCT05304351 Active, not recruiting - Herpes Zoster Clinical Trials

Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older

Start date: February 2, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and immunogenicity of CRV-101, an investigational vaccine compared to Shingrix for the prevention of herpes zoster in adults aged 50 years and older

NCT ID: NCT05303194 Active, not recruiting - Dementia Clinical Trials

Patient Priorities Care for Hispanics With Dementia

PPC-HD
Start date: May 31, 2022
Phase: N/A
Study type: Interventional

Most persons living with dementia (PlwD) have multiple chronic conditions (MCC). Managing MCC typically involves adhering to clinical practice guidelines for single diseases. This approach often results in burdensome care that usually does not reflect what matters most to patients. To address the challenges of caring for patients with MCC, Patient Priorities Care (PPC) was developed - a process that aligns treatment recommendations with patient priorities rather than single-disease guidelines, to improve care. Successful completion of this pragmatic pilot project will help determine how to best embedded PPC in a Healthcare system that serves a large Hispanic population. The investigators will determine if the benefits previously reported with the use of PPC hold in Hispanics with dementia.

NCT ID: NCT05303051 Active, not recruiting - Diabetes Clinical Trials

Validation of the Diabetes Deep Neural Network Score for Diabetes Mellitus Screening

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

The Validation of the Diabetes Deep Neural Network Score (DNN score) for Screening for Type 2 Diabetes Mellitus (diabetes) is a single center, unblinded, observational study to clinically validating a previously developed remote digital biomarker, identified as the DNN score, to screen for diabetes. The previously developed DNN score provides a promising avenue to detect diabetes in these high-risk communities by leveraging photoplethysmography (PPG) technology on the commercial smartphone camera that is highly accessible. Our primary aim is to prospectively clinically validate the PPG DNN algorithm against the reference standards of glycated hemoglobin (HbA1c) for the presence of prevalent diabetes. Our vision is that this clinical trial may ultimately support an application to the Food and Drug Administration so that it can be incorporated into guideline-based screening.